http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Sclerotherapy for Venous Malformations of Head and Neck: Systematic Review and Meta-Analysis
Lucio De Maria,Paolo De Sanctis,Karthik Balakrishnan,Megha Tollefson,Waleed Brinjikji 대한신경중재치료의학회 2020 Neurointervention Vol.15 No.1
We performed a systematic review and meta-analysis of studies performing sclerotherapy for treatment of venous malformations (VMs) of the face, head and neck. It is our hope that data from this study could be used to better inform providers and patients regarding the benefits and risks of percutaneous sclerotherapy for treatment of face, head and neck VMs. We searched PubMed, MEDLINE, and EMBASE from 2000–2018 for studies evaluating the safety and efficacy of percutaneous sclerotherapy of neck, face and head VMs. Two independent reviewers selected studies and abstracted data. The primary outcomes were complete and partial resolution of the VM. Data were analyzed using random-effects meta-analysis. Thirty-seven studies reporting on 2,067 patients were included. The overall rate of complete cure following percutaneous sclerotherapy with any agent was 64.7% (95% confidence interval [CI], 57.4–72.0%). Sodium tetradecyl sulfate had the lowest complete cure rate at 55.5% (95% CI, 36.1–74.9%) while pingyangmycin had the highest cure rate at 82.9% (95% CI, 71.1–94.7%). Overall patient satisfaction rates were 91.0% (95% CI, 86.1–95.9%). Overall quality of life improvement was 78.9% (95% CI, 67.0–90.8%). Overall permanent morbidity/mortality was 0.8% (95% CI, 0.3–1.3%) with no cases of mortality. Our systematic review and meta-analysis of 37 studies and over 2,000 patients found that percutaneous sclerotherapy is a very safe and effective treatment modality for treatment of VMs of the head, neck and face.
Nicosia, Luca,Gentile, Giovanna,Reverberi, Chiara,Minniti, Giuseppe,Valeriani, Maurizio,de Sanctis, Vitaliana,Marinelli, Luca,Cipolla, Fabiola,de Luca, Ottavia,Simmaco, Maurizio,Osti, Mattia F. The Korean Society for Radiation Oncology 2018 Radiation Oncology Journal Vol.36 No.3
Purpose: Standard treatment for locally advanced rectal cancer consists of neoadjuvant radiochemotherapy with concomitant fluoropyrimidine or oxaliplatin and surgery with curative intent. Pathological complete response has shown to be predictive for better outcome and survival; nevertheless there are no biological or genetic factors predictive for response to treatment. We explored the correlation between the single nucleotide polymorphisms (SNPs) GSTP1 (A313G) and XRCC1 (G28152A), and the pathological complete response and survival after neoadjuvant radiochemotherapy in locally advanced rectal cancer patients. Materials and Methods: Genotypes GSTP1 (A313G) and XRCC1 (G28152A) were determined by pyrosequencing technology in 80 patients affected by locally advanced rectal cancer. Results: The overall rate of pathological complete response in our study population was 18.75%. Patients homozygous AA for GSTP1 (A313G) presented a rate of pathological complete response of 26.6% as compared to 8.5% of the AG+GG population (p = 0.04). The heterozygous comparison (AA vs. AG) showed a significant difference in the rate of pathological complete response (26.6% vs. 6.8%; p = 0.034). GSTP1 AA+AG patients presented a 5- and 8-year cancer-specific survival longer than GSTP1 GG patients (87.7% and 83.3% vs. 44.4% and 44.4%, respectively) (p = 0.014). Overall survival showed only a trend toward significance in favor of the haplotypes GSTP1 AA+AG. No significant correlations were found for XRCC1 (G28152A). Conclusion: Our results suggest that GSTP1 (A313G) may predict a higher rate of pathological complete response after neoadjuvant radiochemotherapy and a better outcome, and should be considered in a more extensive analysis with the aim of personalization of radiation treatment.
Luca Nicosia,Giovanna Gentile,Chiara Reverberi,Giuseppe Minniti,Maurizio Valeriani,Vitaliana de Sanctis,Luca Marinelli,Fabiola Cipolla,Ottavia de Luca,Maurizio Simmaco,Mattia F. Osti 대한방사선종양학회 2018 Radiation Oncology Journal Vol.36 No.3
Purpose: Standard treatment for locally advanced rectal cancer consists of neoadjuvant radiochemotherapy with concomitant fluoropyrimidine or oxaliplatin and surgery with curative intent. Pathological complete response has shown to be predictive for better outcome and survival; nevertheless there are no biological or genetic factors predictive for response to treatment. We explored the correlation between the single nucleotide polymorphisms (SNPs) GSTP1 (A313G) and XRCC1 (G28152A), and the pathological complete response and survival after neoadjuvant radiochemotherapy in locally advanced rectal cancer patients. Materials and Methods: Genotypes GSTP1 (A313G) and XRCC1 (G28152A) were determined by pyrosequencing technology in 80 patients affected by locally advanced rectal cancer. Results: The overall rate of pathological complete response in our study population was 18.75%. Patients homozygous AA for GSTP1 (A313G) presented a rate of pathological complete response of 26.6% as compared to 8.5% of the AG+GG population (p = 0.04). The heterozygous comparison (AA vs. AG) showed a significant difference in the rate of pathological complete response (26.6% vs. 6.8%; p = 0.034). GSTP1 AA+AG patients presented a 5- and 8-year cancer-specific survival longer than GSTP1 GG patients (87.7% and 83.3% vs. 44.4% and 44.4%, respectively) (p = 0.014). Overall survival showed only a trend toward significance in favor of the haplotypes GSTP1 AA+AG. No significant correlations were found for XRCC1 (G28152A). Conclusion: Our results suggest that GSTP1 (A313G) may predict a higher rate of pathological complete response after neoadjuvant radiochemotherapy and a better outcome, and should be considered in a more extensive analysis with the aim of personalization of radiation treatment.
CLAS Collaboration,Pereira, S.A.,Mirazita, M.,Rossi, P.,De Sanctis, E.,Niculescu, G.,Niculescu, I.,Stepanyan, S.,Adhikari, K.P.,Aghasyan, M.,Anghinolfi, M.,Baghdasaryan, H.,Ball, J.,Battaglieri, M.,Be North-Holland Pub. Co 2010 Physics letters: B Vol.688 No.4
<P>Differential cross sections of the reaction gamma d -> K+Sigma(-)(p) have been measured with the CLAS detector at Jefferson Lab using incident photons with energies between 1.1 and 3.6 GeV. This is the first complete set of strangeness photoproduction data on the neutron covering a broad angular range. At energies close to threshold and up to E-gamma similar to 1.8 GeV. the shape of the angular distribution is suggestive of the presence of s-channel production mechanisms. For E-gamma > 1.8 GeV, a clear forward peak appears and becomes more prominent as the photon energy increases, suggesting contributions from t-channel production mechanisms. These data can be used to constrain future analysis of this reaction. (c) 2010 Elsevier B.V. All rights reserved.</P>